Laekna, Inc. (HKG:2105)
Hong Kong
· Delayed Price · Currency is HKD 14.41
-0.65 (-4.32%)
At close: Apr 29, 2026
Laekna Revenue
In the year 2025, Laekna had annual revenue of 106.72M CNY. Laekna had revenue of 102.21M in the half year ending December 31, 2025, a decrease of -46,771.23%.
Revenue
106.72M CNY
Revenue Growth
n/a
P/S Ratio
51.03
Revenue / Employee
1.29M CNY
Employees
83
Market Cap
6.06B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 106.72M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 280.00K | 169.00K | 152.25% |
| Dec 31, 2021 | 111.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ocumension Therapeutics | 895.09M |
| Jacobio Pharmaceuticals Group | 59.56M |
| CK Life Sciences Int'l., (Holdings) | 5.41B |
| Guangzhou Innogen Pharmaceutical Group | 146.34M |
| Shandong Boan Biotechnology | 873.36M |
| Shanghai Haohai Biological Technology | 2.73B |
| Abbisko Cayman | 681.17M |
| Qyuns Therapeutics | 897.99M |